Fmoc-Lys(Boc)-OH-13C6,15N2

Names

[ Name ]:
Fmoc-Lys(Boc)-OH-13C6,15N2

[Synonym ]:
L-Lysine-13C6-15N2, N6-[(1,1-dimethylethoxy)carbonyl]-N2-[(9H-fluoren-9-ylmethoxy)carbonyl]-
N2-[(9H-Fluoren-9-ylmethoxy)carbonyl]-N6-{[(2-methyl-2-propanyl)oxy]carbonyl}-L-(13C6,15N2)lysine
N6-(tert-Butoxycarbonyl)-N2-{[(9H-fluoren-9-yl)methoxy]carbonyl}-L-(13C6,15N2)lysine

Biological Activity

[Description]:

Fmoc-L-Lys (Boc)-OH-13C6,15N2 is a 15N-labeled and 13C-labled Triclabendazole.

[Related Catalog]:

Research Areas >> Infection

Signaling Pathways >> Cell Cycle/DNA Damage >> Microtubule/Tubulin

Signaling Pathways >> Cytoskeleton >> Microtubule/Tubulin

[In Vitro]

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[75].

[References]

[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-243.

[2]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-243.

Chemical & Physical Properties

[ Density]:
1.2±0.1 g/cm3

[ Molecular Formula ]:
C₂₀₁₃C₆H₃₂₁₅N₂O₆

[ Molecular Weight ]:
476.48

[ Exact Mass ]:
476.24000

[ PSA ]:
113.96000

[ LogP ]:
5.45510

[ Index of Refraction ]:
1.566

MSDS

Click to get detail MSDS

Safety Information

[ Symbol ]:

GHS09

[ Signal Word ]:
Warning

[ Hazard Statements ]:
H410

[ Precautionary Statements ]:
P273-P501

[ Personal Protective Equipment ]:
Eyeshields;Gloves

[ RIDADR ]:
UN 3077 9 / PGIII